Appetite stimulants

Monopar to Present Results from Analysis of Oropharyngeal Cancer Patients in Completed Phase 2 Validive® Trial at MASCC/ISOO

Retrieved on: 
Thursday, June 24, 2021
Otorhinolaryngology, Medical specialties, Clinical medicine, Chemical compounds, Head and neck cancer, Anxiolytics, Appetite stimulants, Mucositis, Clonidine, Oropharyngeal cancer, Radiation therapy

This analysis provided the rationale for the design of Monopars Phase 2b/3 VOICE trial, which is open and accruing oropharyngeal cancer patients in the US.

Key Points: 
  • This analysis provided the rationale for the design of Monopars Phase 2b/3 VOICE trial, which is open and accruing oropharyngeal cancer patients in the US.
  • For information on registration, visit: https://www.mascc.org/2021-registration
    Validive (clonidine mucobuccal tablet; clonidine MBT) is a novel mucobuccal tablet (MBT) formulation.
  • The mucobuccal tablet provides for prolonged and enhanced local delivery of clonidine to the regions of oral mucosal radiation damage in OPC patients.
  • Examples of these forward-looking statements include: the Companys excitement for the opportunity to continue working towards providing a treatment for severe oral mucositis; and the Phase 2 trial supporting further clinical development in patients with oropharyngeal cancer.

CBD Pet Products Company ElleVet Sciences Hires Vice President of Business Development As Expansion and Growth Continue

Retrieved on: 
Wednesday, June 23, 2021
Euphoriants, Resins, Appetite stimulants, Entheogens, Cannabinoid, Cannabis, CBD, Rosin, Psychoactive drugs, Medical specialties, Drugs

SOUTH PORTLAND, Maine, June 23, 2021 /PRNewswire/ -- ElleVet Sciences , the first company to prove the safety and efficacy of its hemp-based CBD products for pets, is expanding its world-class executive team to include Dave Rosin as Vice President, Business Development, the company announced today.

Key Points: 
  • SOUTH PORTLAND, Maine, June 23, 2021 /PRNewswire/ -- ElleVet Sciences , the first company to prove the safety and efficacy of its hemp-based CBD products for pets, is expanding its world-class executive team to include Dave Rosin as Vice President, Business Development, the company announced today.
  • "Dave's consulting background strengthens our analytical bandwidth and allows ElleVet Sciences to continue to pursue multiple growth opportunities within the cannabinoid industry," says Christian Kjaer, CEO of ElleVet Sciences.
  • Its product remains the only pet CBD + CBDA product on the market proven to work in a clinical trial.
  • ABOUT ELLEVET SCIENCES: ElleVet Sciences is a leading science-focused pet CBD + CBDA company based in Portland, Maine, and the first and only company to conduct clinical trials with proven results using their cannabinoid and terpene oil blend.

Eve & Co Announces the Launch of a New Product The Optimist CBD Bath Bomb

Retrieved on: 
Monday, June 21, 2021
Psychoactive drugs, Euphoriants, Entheogens, Cannabis smoking, Drugs, Appetite stimulants, Medicinal plants, Cannabis, Tetrahydrocannabinol, Hemp, Effects of cannabis

The Optimist CBD Bath Bomb is the fourth cannabis-infused bath bomb product released in Eve & Cos cannabis 2.0 line.

Key Points: 
  • The Optimist CBD Bath Bomb is the fourth cannabis-infused bath bomb product released in Eve & Cos cannabis 2.0 line.
  • This product is handmade with CBD isolate, high-quality, nourishing ingredients, and infused with natural peppermint and eucalyptus essential oils.
  • This formulation of The Optimist CBD Bath Bomb is virtually THC-free with specific terpene and aromatic properties and is meant to relax the mind and restore the body.
  • We are excited to launch this product and add to our highly successful line of bath bombs, which continues to sell extremely well across Canada.

Your CBD Store Unveils New "BEYOND by SUNMED" Line, Using Innovative Process to Create Unprecedented Fuller Spectrum Experience

Retrieved on: 
Friday, June 18, 2021
Euphoriants, Entheogens, Psychoactive drugs, Drugs, Appetite stimulants, Cannabis, Cannabinoid, Tetrahydrocannabinol, Neurochemistry

"BEYOND uses 400% more minor cannabinoids rather than using CBD as an isolate, achieving maximum benefits for CBD users seeking a heightened experience.

Key Points: 
  • "BEYOND uses 400% more minor cannabinoids rather than using CBD as an isolate, achieving maximum benefits for CBD users seeking a heightened experience.
  • The BEYOND line features more CBG, CBC, CBN and THC-V among other beneficial compounds to create a cutting-edge fuller spectrum.
  • Since its launch, Your CBD Store has expanded to more than 600 affiliate stores, 200 of which are franchise locations.
  • Its parent company, Sunflora Inc., produces quality products for health and wellness, skincare, and pets.

Decibel Announces Launch of Premium Brand "Pressed by Qwest" and New Flower, Vape, and Concentrate Products

Retrieved on: 
Thursday, June 17, 2021
Lumen Technologies, Appetite stimulants, Entheogens, Euphoriants, Drugs, Psychoactive drugs, Medical specialties, Qwest, Brand, Tetrahydrocannabinol, Cannabis

"Our strategic focus remains on expanding our market share as we launch our premium cannabis 2.0 products and increasing our flower capacity from 1,800 kg to 9,000 kg over this year."

Key Points: 
  • "Our strategic focus remains on expanding our market share as we launch our premium cannabis 2.0 products and increasing our flower capacity from 1,800 kg to 9,000 kg over this year."
  • In the second half of 2021, Decibel will launch a brand-new set of rare cultivars under the Qwest and Qwest Reserve brands.
  • The Company expects to launch seven new cultivars in 2021 as well as, a new high THC, pre-milled flower product under the Blendcraft by Qwest Brand.
  • The launch of Pressed by Qwest, a concentrate focused brand under the Qwest Family of Brands, allows Decibel to have a format focused brand, concentrate consumers can trust to deliver exceptional quality.

Texas Original Compassionate Cultivation Launches the State’s First THC-only Tincture

Retrieved on: 
Wednesday, June 16, 2021
Oncology, Alternative medicine, Retail, Health, Tobacco, General Health, Drugs, Psychoactive drugs, Medicine, Appetite stimulants, Entheogens, Euphoriants, Herbalism, Medicinal plants, Cannabis, Tetrahydrocannabinol, Legality of cannabis, Medical cannabis

Texas Original Compassionate Cultivation (TOCC), Texas leading medical cannabis provider, today released the states first 0:1 THC-only medical cannabis tincture.

Key Points: 
  • Texas Original Compassionate Cultivation (TOCC), Texas leading medical cannabis provider, today released the states first 0:1 THC-only medical cannabis tincture.
  • The tincture will be available to qualifying patients throughout Texas under the states Compassionate Use Program (CUP).
  • View the full release here: https://www.businesswire.com/news/home/20210616005235/en/
    Texas Original Compassionate Cultivation, Texas leading medical cannabis provider, launched the states first 0:1 THC-only medical cannabis tincture for qualifying patients.
  • Texas Original Compassionate Cultivation (TOCC) is the leading licensed medical marijuana producer in Texas, working alongside physicians to provide the highest quality cannabis medicine to patients and families seeking relief across the state.

Parallel's goodblend™ Texas Launches the First CBN Cannabis Product Line for Patients Through Texas Compassionate Use Program

Retrieved on: 
Wednesday, June 16, 2021
Psychoactive drugs, Drugs, Branches of biology, Euphoriants, Appetite stimulants, Entheogens, Herbalism, Medicinal plants, Cannabis, Tetrahydrocannabinol, Cannabinoid, Medical cannabis

"We are excited to debut yet another first-to-market cannabis product in Texas and to extend our Surterra Wellness line into the Massachusetts market with the launch of Dream +CBN.

Key Points: 
  • "We are excited to debut yet another first-to-market cannabis product in Texas and to extend our Surterra Wellness line into the Massachusetts market with the launch of Dream +CBN.
  • "Dream +CBN exemplifies Parallel's emphasis on bringing patients a wide variety of innovative product formats and proprietary cannabinoid blends through our dedicated R&D team."
  • In Texas, the Dream +CBN product line comes in a 15mg dose of CBN and THC per milliliter (ml), contains a proprietary Dream terpene profile, and is infused with the cannabinoid ratio of 2 CBN : 1 THC.
  • "goodblend Texas is proud to be the first medical cannabis dispensary in Texas to offer a product with the rare cannabinoid CBN to qualifying patients across the Lone Star State through the Compassionate Use Program.

Parallel's goodblend™ Texas Launches the First CBN Cannabis Product Line for Patients Through Texas Compassionate Use Program

Retrieved on: 
Wednesday, June 16, 2021
Psychoactive drugs, Drugs, Branches of biology, Euphoriants, Appetite stimulants, Entheogens, Herbalism, Medicinal plants, Cannabis, Tetrahydrocannabinol, Cannabinoid, Medical cannabis

"We are excited to debut yet another first-to-market cannabis product in Texas and to extend our Surterra Wellness line into the Massachusetts market with the launch of Dream +CBN.

Key Points: 
  • "We are excited to debut yet another first-to-market cannabis product in Texas and to extend our Surterra Wellness line into the Massachusetts market with the launch of Dream +CBN.
  • "Dream +CBN exemplifies Parallel's emphasis on bringing patients a wide variety of innovative product formats and proprietary cannabinoid blends through our dedicated R&D team."
  • In Texas, the Dream +CBN product line comes in a 15mg dose of CBN and THC per milliliter (ml), contains a proprietary Dream terpene profile, and is infused with the cannabinoid ratio of 2 CBN : 1 THC.
  • "goodblend Texas is proud to be the first medical cannabis dispensary in Texas to offer a product with the rare cannabinoid CBN to qualifying patients across the Lone Star State through the Compassionate Use Program.

New Leaf Ventures Introduces Astara THC and CBD Infused Beverages

Retrieved on: 
Tuesday, June 15, 2021
Psychoactive drugs, Entheogens, Euphoriants, Drugs, Appetite stimulants, Cannabis smoking, Medicinal plants, Branches of biology, Cannabis, Tetrahydrocannabinol, Astara, Cider

The name Astara means "of the stars" and is formulated for a mind-expanding experience aimed at elevating mood without a hangover residual effect.

Key Points: 
  • The name Astara means "of the stars" and is formulated for a mind-expanding experience aimed at elevating mood without a hangover residual effect.
  • Astara will hit the market with a low calorie, craft beverage that tastes good without the bitterness of other cannabis drinks.
  • Astara delivers a revolutionary formulation of crisp, clean flavor in a low dose THC beverage designed to be consumed over time like beer or cider.
  • About New Leaf Ventures Inc. (CSE: NLV) (OTC: NLVVF)
    New Leaf Ventures Inc. is developing a cannabis sector-based scalable securities concept of focused financing and applied management to achieve earnings growth through targeted investment.

THC Engages Oak Hill Financial Inc. for Investor Relations and Advisory Services

Retrieved on: 
Tuesday, June 15, 2021
Drugs, Appetite stimulants, Entheogens, Euphoriants, Psychoactive drugs, Antiemetics, Tetrahydrocannabinol, Medical specialties

VANCOUVER, BC, June 15, 2021 /PRNewswire/ -- THC BioMed Intl Ltd. ("THC" or the "Company") (CSE: THC) is pleased to announce that it has retained the services of Toronto-based Oak Hill Financial ("Oak Hill") to assist with investor relations activities.

Key Points: 
  • VANCOUVER, BC, June 15, 2021 /PRNewswire/ -- THC BioMed Intl Ltd. ("THC" or the "Company") (CSE: THC) is pleased to announce that it has retained the services of Toronto-based Oak Hill Financial ("Oak Hill") to assist with investor relations activities.
  • THC has partnered with Oak Hill to enhance its visibility and profile to the public and in the financial community.
  • Oak Hill is to provide THC with Canadian investor relations advisory activities.
  • Aside from the options issued by THC to Oak Hill, Oak Hill does not have any additional interest in THC's securities, directly or indirectly, or any right or intent to acquire such an interest.